Deuruxolitinib 8 or 12 mg BID improved SALT20 response versus placebo in severe alopecia areata
Hair Regrowth Drug Shows Strong Results in Major Trial
This Phase 3 randomized, double-blind, placebo-controlled, multicenter trial enrolled 517 adults aged 18 to 65 years with severe chronic alo…
A new drug helped 38% of adults with severe hair loss regrow most of their hair in just six months during a major trial.
Mazdutide monotherapy reduces HbA1c and promotes weight loss in Chinese adults with type 2 diabetes over 48 weeks
New Drug Lowers Sugar and Shrinks Weight in Diabetes
This phase 3 randomized controlled trial evaluated weekly subcutaneous mazdutide (4 mg or 6 mg) versus placebo in Chinese adults with type 2…
A new diabetes drug called mazdutide lowers blood sugar and shrinks weight in adults who struggle with diet and exercise alone.
Phase 2 trial tests single-dose IV iron isomaltoside in severe aortic stenosis with iron deficiency
Early study suggests iron treatment may help heart function in severe aortic stenosis patients
This Phase 2, double-blind, randomized, placebo-controlled trial tested a single intravenous dose of iron isomaltoside versus placebo in pat…
Treating iron deficiency may improve exercise capacity and reduce fatigue in people with severe aortic stenosis, according to early trial re…
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy in Chinese adults with advanced biliary tract carcinoma
Could adding pembrolizumab help Chinese adults live longer with advanced biliary tract carcinoma?
This phase 3 randomized controlled trial enrolled 158 Chinese adults with advanced or unresectable biliary tract carcinoma.
A completed study in China compared adding pembrolizumab to chemotherapy for advanced bile duct cancer, tracking how long 158 adults survive…
AZD7442 showed no benefit over placebo and increased rehospitalization risk in hospitalized COVID-19 adults
A COVID Antibody Drug That Looked Promising Didn't Deliver
This Phase 3 randomized multicentre trial evaluated tixagevimab-cilgavimab (AZD7442) versus placebo in 237 hospitalized adults with PCR-conf…
A rigorous 15-month trial found that a promising COVID antibody drug offered no clinical benefit to hospitalized patients and led to more re…
Pyridostigmine improves symptoms and reduces costs in adults with AChR MG in a crossover trial
The Pill Millions Take Daily Finally Gets Proof It Works
A randomized, double-blind, placebo-controlled crossover trial in 19 adults with anti-acetylcholine receptor-positive myasthenia gravis (ACh…
After decades of widespread use, a medication that helps people with myasthenia gravis regain muscle control now has its first rigorous clin…
Memantine reduces opioid use but not pain in knee osteoarthritis patients after surgery
This Common Memory Drug Cuts Opioid Use After Knee Replacement
A randomized controlled trial in adults with knee osteoarthritis found memantine did not significantly lower pain scores versus placebo, but…
A drug already approved for Alzheimer's disease may help knee replacement patients rely less on opioids during recovery — even if it does no…
Pitavastatin showed no difference in health-related quality of life compared with placebo in people with HIV
Why Heart Risk Factors Drag Down Daily Wellbeing for People With HIV
This randomized controlled trial evaluated pitavastatin versus placebo in 733 people with HIV aged 40 to 75 years on antiretroviral therapy …
Common heart risks like smoking and high BMI hurt daily physical wellbeing for people with HIV, while statins showed no visible improvement …
Nerinetide showed no significant association with brain volume changes in stroke patients receiving endovascular therapy
A Hidden Brain Injury Keeps Growing After a Stroke
This prospective, multisite MRI sub-study of the ESCAPE-NA1 trial included 43 patients receiving endovascular therapy (EVT) for stroke.
A stroke's damage keeps unfolding for three months as hidden brain shrinkage spreads, offering a roadmap for new protective drugs during the…
Galantamine showed no cognitive benefit in people with HIV-associated neurocognitive disorders
Why Galantamine Failed to Help
In a double-blind, randomized, placebo-controlled crossover study, people with HIV on antiretroviral therapy received galantamine or placebo…
Galantamine, a drug used for memory loss, did not improve brain fog in people with HIV, even though it increased a key inflammation marker.
Oral semaglutide reduces composite heart failure outcomes in patients with type 2 diabetes and heart failure history
A Common Diabetes Pill May Also Protect Your Heart From Failure
This secondary analysis of a phase 3b randomized clinical trial evaluated once-daily oral semaglutide versus placebo in 9,650 participants w…
For millions living with type 2 diabetes and a struggling heart, a medication they might already be taking could offer a powerful, two-in-on…
Lecanemab slowed cognitive decline in ApoE4 non-carriers and heterozygotes with early Alzheimer's disease
A New Alzheimer's Drug Shows Stronger Promise for Most People at Risk
This Phase 3 subgroup analysis of an RCT evaluated lecanemab in 1,521 individuals with early Alzheimer's disease who were ApoE4 non-carriers…
For the majority of people facing early Alzheimer's, starting this treatment sooner may help preserve more of their daily life for longer.